However, previous studies have not specifically reported outcomes in HER2-positive cohorts, and whether the addition of HER2 blockade and/or immune checkpoint blockade to chemotherapy would have clinical benefits for patients with potentially resectable HER2-positive GC remains unclear. The gene discussed is ERBB2; the disease is gastric cancer.